Johnson & Johnson COVID-19 Vaccine Vials DADO RUVIC / Reuters
Johnson & Johnson Covid-19 Single-Dose Vaccine is 85% Safe and Effective, According to Information Released by the Food and Drug Administration of the United States (FDA, for its acronym in English), the authority responsible for the authorization of drugs. This declaration paves the way for the emergency approval of this new option to fight the pandemic, requested on February 5.
According to the information provided by the pharmaceutical company to the FDA, its vaccine is effective even with the new variants of the virus, according to a clinical trial on 44,000 people. The effectiveness ranges from 85.6% in tests developed in the United States to 81.7% in South Africa, where the presence of specific mutations has reduced the positive effects of vaccination. In general figures, always according to the information provided by the company, the vaccine is 86.85% effective against severe cases of covid, but it is a low percentage when it comes to its general efficacy against the disease. In the same way, in the technical analysis of the FDA after the clinical trial, no notable side effects or serious allergic reactions have been observed.
Based on these new data, the United States plans to authorize this Saturday the use of the Johnson & Johnson vaccine and incorporate it into the pharmacological arsenal deployed to curb the pandemic.
As an advantage over the Moderna and Pfizer vaccines, Johnson & Johnson's single-dose drug does not require special refrigeration and allows its storage in conventional chambers for three months, that makes it easy to distribute.
The company's new data, published by the FDA, increases the efficacy reported in the first tests and the protection against the serious development of the disease and the spread of the virus. In this sense, the effectiveness obtained in South Africa has increased by seven points in relation to the data from the first trials. However, its results are still lower than those achieved by the Moderna and Pfizer vaccines (developed with BioNTech), which have yielded results greater than 95% efficacy. However, it is higher than the levels reached by AstraZeneca vials, which are around 80%, although its effectiveness in the older population is debated.
The South African variant of the virus has become an obstacle for vaccines and not only for the last one developed by the North American pharmaceutical company. Novavax's has registered an efficiency of 49% in South Africa and the Government of this country has rejected the use of the AstraZeneca-Oxford option due to the poor results obtained
According to the company, once its emergency use is approved, Four million doses will be distributed.
You can follow Materia at Facebook , Twitter , Instagram or subscribe here to our
newsletter Source: Elpais